Related references
Note: Only part of the references are listed.Endothelial life discontinues without Erk
Yihai Cao
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Propranolol exhibits activity against hemangiomas independent of beta blockade
Maiko Sasaki et al.
NPJ PRECISION ONCOLOGY (2019)
Anti-Angiogenics: Their Value in Colorectal Cancer Therapy
Andreas Seeber et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling
Kayoko Hosaka et al.
CELL DISCOVERY (2018)
FGF-dependent metabolic control of vascular development
Pengchun Yu et al.
NATURE (2017)
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
Yunlong Yang et al.
NATURE COMMUNICATIONS (2016)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
VEGF-targeted cancer therapeutics - paradoxical effects in endocrine organs
Yihai Cao
NATURE REVIEWS ENDOCRINOLOGY (2014)
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis
Kayoko Hosaka et al.
NATURE COMMUNICATIONS (2013)
PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells
Yuan Xue et al.
NATURE MEDICINE (2012)
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Baskaran Govindarajan et al.
VASCULAR CELL (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Annika Armulik et al.
DEVELOPMENTAL CELL (2011)
Tumor angiogenesis and molecular targets for therapy
Yihai Cao
Frontiers in Bioscience-Landmark (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
Eva-Maria Hedlund et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Drug Insight: antiangiogenic therapies for gastrointestinal cancers - focus on monoclonal antibodies
Anke Reinacher-Schick et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis
Lars Johan Nissen et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB
B Govindarajan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Endothelial-pericyte interactions in angiogenesis
H Gerhardt et al.
CELL AND TISSUE RESEARCH (2003)
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
H Gerhardt et al.
JOURNAL OF CELL BIOLOGY (2003)
Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
RH Cao et al.
NATURE MEDICINE (2003)
Share Paper
